Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.

Richard E ClarkAmmar A BasabrainGemma M AustinAlison K HolcroftSandra LoaizaJane F ApperleyChristopher LawLaura ScottAlexandra D ParryLaura Jayne BonnettClaire M Lucas

Published in: Cancers (2021)

These data confirm that high diagnostic CIP2A levels correlate with subsequent disease progression and treatment failure. CIP2A is a simple diagnostic biomarker that may be useful in planning treatment strategies.

Keyphrases

bone marrow
dendritic cells
electronic health record
big data
combination therapy
deep learning
artificial intelligence